Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and...
Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and operating costs by 50%, and end Phase III trials of its ixmyelocel-T drug for patients with critical limb ischemia - when there is an sudden lack of blood flow to a limb - as it was unable to bring in a partner. Instead, Aastrom will focus on Phase 2b trials of ixCELL for treating dilated cardiomyopathy (heart muscle disease). (PR)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs